A pooled mutant KRAS peptide vaccine activates polyfunctional T cell responses in patients with resected pancreatic cancer

被引：3
|
作者：
Huff, Amanda L.
Haldar, Saurav D.
Davis-Marcisak, Emily
Heumann, Thatcher
Longway, Gabriella
Hernandez, Alexei
Konig, Maximillian F.
Mog, Brian
Danilova, Ludmila
Kagohara, Luciane
Nauroth, Julie M.
Thomas, Amy M.
Fertig, Elana J.
Ho, Won Jin
Jaffee, Elizabeth M.
Azad, Nilo
Zaidi, Neeha
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-LB197
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A pooled shRNA screen for erlotinib sensitizers in Kras-mutant non-small cell lung cancer
    Cordes, Shaun
    Dompe, Nick
    Lee, James
    Li, Li
    Rivers, Celina
    Tang, Zhijun
    Luk, Wilman
    Bennett, Greg
    Shames, David
    Modrusan, Zora
    Davis, David P.
    CANCER RESEARCH, 2010, 70
  • [22] Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients
    Miyazawa, Motoki
    Katsuda, Masahiro
    Maguchi, Hiroyuki
    Katanuma, Akio
    Ishii, Hiroshi
    Ozaka, Masato
    Yamao, Kenji
    Imaoka, Hiroshi
    Kawai, Manabu
    Hirono, Seiko
    Okada, Ken-ichi
    Yamaue, Hiroki
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (04) : 973 - 982
  • [23] Ras peptide vaccination in resected pancreatic cancer patients; Safety, immune response and survival
    Bernhardt, S
    Gjertsen, MK
    Moeller, M
    Eriksen, JA
    Soereide, O
    Gladhaug, A
    Bakka, A
    Gaudernack, G
    Buanes, T
    GASTROENTEROLOGY, 2004, 126 (04) : A623 - A623
  • [24] A novel therapeutic HBV vaccine candidate induces strong polyfunctional cytotoxic T cell responses in mice
    Boudewijns, Robbert
    Ma, Ji
    Neyts, Johan
    Dallmeier, Kai
    JHEP REPORTS, 2021, 3 (04)
  • [25] Characterization of long-term effector-memory T-cell responses in patients with resected high-risk melanoma receiving a melanoma peptide vaccine
    Chiong, B
    Wong, R
    Lee, P
    Delto, J
    Scotland, R
    Lau, R
    Weber, J
    JOURNAL OF IMMUNOTHERAPY, 2004, 27 (05) : 368 - 379
  • [26] Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients
    Okuyama, Ryuji
    Aruga, Atsushi
    Hatori, Takashi
    Takeda, Kazuyoshi
    Yamamoto, Masakazu
    ONCOIMMUNOLOGY, 2013, 2 (11):
  • [27] Mutant Kras vaccination combined with T regulatory cell depletion effectively delays progression of premalignant lesions in a transgenic model of pancreatic cancer
    Saenger, Yvonne
    Kafrouni, Michel
    Leubner, Ashley
    Herman, Joseph
    Dubensky, Thomas
    Lauer, Peter
    Jaffee, Elizabeth
    CANCER RESEARCH, 2009, 69
  • [28] Phase I study of lapatinib and trametinib in patients with KRAS mutant colorectal, non-small cell lung and pancreatic cancer
    Huijberts, S. C. F. A.
    van Brummelen, E.
    van Geel, R.
    Opdam, F. L.
    Marchetti, S.
    Steeghs, N.
    Pulleman, S.
    Thijssen, B.
    Rosing, H.
    Monkhorst, K.
    Huitema, A. D. R.
    Beijnen, J. H.
    Bernards, R.
    Schellens, J. H. M.
    ANNALS OF ONCOLOGY, 2019, 30 : 178 - +
  • [29] Adjuvant combination therapy with gemcitabine and autologous γδ T-cell transfer in patients with curatively resected pancreatic cancer
    Aoki, Taku
    Viatsushita, Hirokazu
    Hoshikawa, Mayumi
    Hasegawa, Kiyoshi
    Kokudo, Norihiro
    Kakimi, Kazuhiro
    CYTOTHERAPY, 2017, 19 (04) : 473 - 485
  • [30] Cancer vaccine induces potent T cell responses — but is it enough?
    Anjali Rohatgi
    John M. Kirkwood
    Nature Reviews Clinical Oncology, 2020, 17 : 721 - 722
12345